Core Insights - NewcelX has announced a strategic collaboration with Eledon Pharmaceuticals to advance the NCEL-101 program for Type 1 Diabetes, integrating stem-cell-derived islets with targeted immune modulation [1] - The collaboration aims to support durable, immune-protected islet replacement and advance a potential functional cure for Type 1 Diabetes [1] - Eledon's investigational anti-CD40L monoclonal antibody, tegoprubart, will be utilized to modulate immune activation pathways central to T-cell–mediated transplant rejection [1] Collaboration Details - The partnership is designed to leverage clinical experience from over 100 transplant patients treated with tegoprubart, providing insights relevant to cell replacement therapies [1] - This collaboration is expected to accelerate timelines, establish a well-defined regulatory pathway, and enhance development visibility for NewcelX's clinical programs [1] - The integration of immune modulation with NCEL-101 is intended to enhance the durability and graft survival of the cells [1] Company Overview - NewcelX is focused on developing stem-cell-derived therapies for Type 1 Diabetes, with NCEL-101 as its lead program aimed at restoring functional insulin production through scalable, off-the-shelf cell replacement [1] - The company is advancing a comprehensive therapeutic approach that integrates cell therapy, immune protection, and translational science to address critical unmet medical needs in Type 1 Diabetes [1] - The collaboration with Eledon represents a strategic milestone for NewcelX, enhancing its execution-focused clinical programs and broadening collaboration with leaders in immune biology and transplant medicine [1]